PL3326643T3 - Chimeryczne i hybrydowe polipeptydy czynnika VIII-FC oraz sposoby ich zastosowania - Google Patents

Chimeryczne i hybrydowe polipeptydy czynnika VIII-FC oraz sposoby ich zastosowania

Info

Publication number
PL3326643T3
PL3326643T3 PL17194648T PL17194648T PL3326643T3 PL 3326643 T3 PL3326643 T3 PL 3326643T3 PL 17194648 T PL17194648 T PL 17194648T PL 17194648 T PL17194648 T PL 17194648T PL 3326643 T3 PL3326643 T3 PL 3326643T3
Authority
PL
Poland
Prior art keywords
chimeric
methods
factor viii
hybrid polypeptides
polypeptides
Prior art date
Application number
PL17194648T
Other languages
English (en)
Inventor
Jennifer A. Dumont
Susan Low
Alan J. Bitonti
Glenn Pierce
Alvin Luk
Haiyan Jiang
Byron Mckinney
Matt Ottmer
Jurg M. Sommer
Karen Nugent
Lian Li
Robert Peters
Original Assignee
Bioverativ Therapeutics Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioverativ Therapeutics Inc. filed Critical Bioverativ Therapeutics Inc.
Publication of PL3326643T3 publication Critical patent/PL3326643T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PL17194648T 2009-12-06 2010-12-06 Chimeryczne i hybrydowe polipeptydy czynnika VIII-FC oraz sposoby ich zastosowania PL3326643T3 (pl)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US26707009P 2009-12-06 2009-12-06
US28505409P 2009-12-09 2009-12-09
US30159210P 2010-02-04 2010-02-04
US36306510P 2010-07-09 2010-07-09
US37311310P 2010-08-12 2010-08-12
US41092910P 2010-11-07 2010-11-07
US41967610P 2010-12-03 2010-12-03
PCT/US2010/059136 WO2011069164A2 (en) 2009-12-06 2010-12-06 Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
EP10835255.0A EP2506868B1 (en) 2009-12-06 2010-12-06 Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
EP17194648.6A EP3326643B1 (en) 2009-12-06 2010-12-06 Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof

Publications (1)

Publication Number Publication Date
PL3326643T3 true PL3326643T3 (pl) 2021-10-25

Family

ID=44115536

Family Applications (2)

Application Number Title Priority Date Filing Date
PL10835255T PL2506868T3 (pl) 2009-12-06 2010-12-06 Chimeryczne i hybrydowe polipeptydy czynnika krzepnięcia viii-fc oraz sposoby ich stosowania
PL17194648T PL3326643T3 (pl) 2009-12-06 2010-12-06 Chimeryczne i hybrydowe polipeptydy czynnika VIII-FC oraz sposoby ich zastosowania

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL10835255T PL2506868T3 (pl) 2009-12-06 2010-12-06 Chimeryczne i hybrydowe polipeptydy czynnika krzepnięcia viii-fc oraz sposoby ich stosowania

Country Status (30)

Country Link
US (5) US9050318B2 (pl)
EP (4) EP2506868B1 (pl)
JP (8) JP5903048B2 (pl)
KR (1) KR101770849B1 (pl)
CN (1) CN102791285A (pl)
AU (6) AU2010325787B2 (pl)
BR (1) BR112012013502A2 (pl)
CA (2) CA3121739A1 (pl)
CO (1) CO6561782A2 (pl)
CY (2) CY1119919T1 (pl)
DK (1) DK2506868T3 (pl)
EA (2) EA025416B1 (pl)
ES (2) ES2659888T3 (pl)
HR (2) HRP20180135T1 (pl)
HU (1) HUE036233T2 (pl)
IL (2) IL220204B (pl)
LT (1) LT2506868T (pl)
ME (1) ME02964B (pl)
MX (3) MX336830B (pl)
MY (1) MY159135A (pl)
NO (1) NO2506868T3 (pl)
NZ (2) NZ600709A (pl)
PL (2) PL2506868T3 (pl)
PT (2) PT2506868T (pl)
RS (1) RS56957B1 (pl)
SG (3) SG181130A1 (pl)
SI (1) SI2506868T1 (pl)
SM (1) SMT201800099T1 (pl)
WO (1) WO2011069164A2 (pl)
ZA (1) ZA201204874B (pl)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6263355A (ja) * 1985-09-13 1987-03-20 Hitachi Ltd バツテリバツクアツプｒａｍのチエツク方法
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
KR101544245B1 (ko) 2009-02-03 2015-08-12 아뮤닉스 오퍼레이팅 인코포레이티드 연장된 재조합 폴리펩티드 및 이를 포함하는 조성물
AU2010290131C1 (en) 2009-08-24 2015-12-03 Amunix Operating Inc. Coagulation factor VII compositions and methods of making and using same
EP2506868B1 (en) 2009-12-06 2017-11-15 Bioverativ Therapeutics Inc. Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
HRP20191305T1 (hr) 2010-07-09 2019-10-18 Bioverativ Therapeutics Inc. Preradive jednolančane molekule i polipeptidi izrađeni koristeći iste
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2622064B1 (en) 2010-10-01 2019-05-29 Modernatx, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
EP2635310A2 (en) 2010-11-05 2013-09-11 Rinat Neuroscience Corp. Engineered polypeptide conjugates and methods for making thereof using transglutaminase
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
WO2012170969A2 (en) 2011-06-10 2012-12-13 Biogen Idec Ma Inc. Pro-coagulant compounds and methods of use thereof
HUE043763T2 (hu) * 2011-07-08 2019-09-30 Bioverativ Therapeutics Inc VIII-as faktor kiméra és hibrid polipeptidek, és azok alkalmazási eljárásai
US10656167B2 (en) * 2011-07-25 2020-05-19 Bioverativ Therapeutics Inc. Assays to monitor bleeding disorders
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP3492109B1 (en) 2011-10-03 2020-03-04 ModernaTX, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
HRP20220717T1 (hr) 2011-12-16 2022-07-22 Modernatx, Inc. Modificirani pripravci mrna
US11370827B2 (en) * 2012-01-12 2022-06-28 Bioverativ Therapeutics Inc. Chimeric factor VIII polypeptides and uses thereof
SI2802668T1 (sl) * 2012-01-12 2019-01-31 Bioverativ Therapeutics Inc. Zmanjšanje imunogeničnosti proti faktorju VIII pri posameznikih, ki se zdravijo zaradi faktorja VIII
EA201491470A1 (ru) * 2012-02-15 2015-01-30 Амуникс Оперэйтинг Инк. Композиции фактора viii и способы получения и использования подобных
HRP20190454T1 (hr) 2012-02-15 2019-05-03 Bioverativ Therapeutics Inc. Rekombinantni faktor viii proteini
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
WO2013151665A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
EP2836518B1 (en) 2012-04-11 2019-01-02 Bioverativ Therapeutics Inc. Methods of detecting glycosaminoglycans
JP2015525222A (ja) 2012-06-08 2015-09-03 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． キメラ性凝固因子
JP2015521589A (ja) 2012-06-08 2015-07-30 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． プロコアグラント化合物
EP3404105A1 (en) * 2012-07-06 2018-11-21 Bioverativ Therapeutics Inc. Cell line expressing single chain factor viii polypeptides and uses thereof
MX381011B (es) * 2012-07-11 2025-03-12 Bioverativ Therapeutics Inc Complejo del factor viii con xten y proteína del factor von willebrand, y sus usos.
US10001495B2 (en) 2012-07-25 2018-06-19 Bioverativ Therapeutics Inc. Blood factor monitoring assay and uses thereof
US10391152B2 (en) 2012-10-18 2019-08-27 Bioverativ Therapeutics Inc. Methods of using a fixed dose of a clotting factor
EP2914293A4 (en) * 2012-10-30 2016-04-20 Biogen Ma Inc METHOD OF USE OF FVIII POLYPEPTIDE
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
US10717965B2 (en) 2013-01-10 2020-07-21 Gloriana Therapeutics, Inc. Mammalian cell culture-produced neublastin antibodies
FI3889173T3 (fi) * 2013-02-15 2023-10-02 Bioverativ Therapeutics Inc Optimoitu tekijä viii:n geeni
ES2926798T3 (es) * 2013-03-15 2022-10-28 Bioverativ Therapeutics Inc Formulaciones de polipéptido de factor VIII
US9090697B2 (en) * 2013-03-15 2015-07-28 Bayer Healthcare Llc Methods for treating bleeding disorders
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10364288B2 (en) 2013-05-24 2019-07-30 Biogen Ma Inc. Anti-GPIIB/IIIA antibodies or uses thereof
TW201536811A (zh) * 2013-05-31 2015-10-01 Biogen Idec Inc 嵌合ｆｖｉｉ－ｘｔｅｎ分子及其用途
KR102397974B1 (ko) * 2013-06-20 2022-05-13 다케다 야쿠힌 고교 가부시키가이샤 약물동역학 약물 투약 요법의 제공
EP3013359A4 (en) * 2013-06-28 2017-01-25 Biogen MA Inc. Thrombin cleavable linker
SG10201913738YA (en) * 2013-06-28 2020-03-30 Bioverativ Therapeutics Inc Thrombin cleavable linker with xten and its uses thereof
EP3027224B1 (en) 2013-07-31 2020-06-03 Rinat Neuroscience Corp. Engineered polypeptide conjugates using transglutaminase
EP4108254A1 (en) 2013-08-14 2022-12-28 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
WO2015023891A2 (en) 2013-08-14 2015-02-19 Biogen Idec Ma Inc. Factor viii-xten fusions and uses thereof
EP3048899B1 (en) 2013-09-25 2021-09-08 Bioverativ Therapeutics Inc. On-column viral inactivation methods
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
SG11201602503TA (en) 2013-10-03 2016-04-28 Moderna Therapeutics Inc Polynucleotides encoding low density lipoprotein receptor
US10584147B2 (en) 2013-11-08 2020-03-10 Biovertiv Therapeutics Inc. Procoagulant fusion compound
EP4332839A3 (en) * 2013-12-06 2024-06-05 Bioverativ Therapeutics Inc. Population pharmacokinetics tools and uses thereof
EP3083933B1 (en) 2013-12-20 2026-01-21 Biogen MA Inc. Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality
RS65533B1 (sr) 2014-01-10 2024-06-28 Bioverativ Therapeutics Inc Himerni proteini faktora viii i njihova upotreba
KR20230136616A (ko) 2014-02-04 2023-09-26 바이오젠 엠에이 인코포레이티드 번역 후 변형을 강화시키기 위한 통류 방식 양이온교환 크로마토그래피의 용도
WO2015148454A1 (en) * 2014-03-28 2015-10-01 Asklepios Biopharmaceutical, Inc. Optimized and modified factor viii genes for gene therapy
AU2015249452B2 (en) 2014-04-25 2017-10-26 Pfizer Inc. Antibody-drug conjugates with high drug loading
US11008561B2 (en) 2014-06-30 2021-05-18 Bioverativ Therapeutics Inc. Optimized factor IX gene
BR112017007765B1 (pt) 2014-10-14 2023-10-03 Halozyme, Inc Composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo
MA40835A (fr) 2014-10-23 2017-08-29 Biogen Ma Inc Anticorps anti-gpiib/iiia et leurs utilisations
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
MA40861A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Anticorps anti-glycoprotéines iib/iiia
WO2017024060A1 (en) 2015-08-03 2017-02-09 Biogen Ma Inc. Factor ix fusion proteins and methods of making and using same
US11560418B2 (en) 2015-10-20 2023-01-24 The University Of North Carolina At Chapel Hill Methods and compositions for modified factor IX fusion proteins
HRP20221089T1 (hr) 2016-02-01 2022-11-25 Bioverativ Therapeutics Inc. Optimizirani geni faktora viii
EA201892347A1 (ru) 2016-04-15 2019-04-30 Баксалта Инкорпорейтед Способ и устройство для предоставления фармакокинетической схемы дозирования лекарственных препаратов
TW201739448A (zh) * 2016-05-06 2017-11-16 安成生物科技股份有限公司 用於治療及/或預防血液相關疾病之方法及配方
EP3476937A4 (en) * 2016-06-24 2019-12-04 Mogam Institute for Biomedical Research CHIMERIC PROTEIN WITH FVIII AND VWF FACTORS AND USE THEREOF
KR20190077306A (ko) 2016-08-05 2019-07-03 메디뮨 엘엘씨 항-o2 항체 및 이의 용도
CN106279437B (zh) * 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
CN107759697B (zh) 2016-08-19 2023-03-24 安源医药科技（上海）有限公司 制备融合蛋白的方法
AU2017346488A1 (en) 2016-10-19 2019-05-30 Humabs Biomed Sa Anti-O1 antibodies and uses thereof
CA3045660A1 (en) 2016-12-02 2018-06-07 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
WO2018102760A1 (en) 2016-12-02 2018-06-07 Bioverativ Therapeutics Inc. Methods of inducing immune tolerance to clotting factors
CN108239151B (zh) * 2016-12-23 2020-07-03 海门晟斯生物制药有限公司 重组单链人FVIII-Fc融合蛋白及其应用
US10896749B2 (en) * 2017-01-27 2021-01-19 Shire Human Genetic Therapies, Inc. Drug monitoring tool
MX2019009063A (es) 2017-01-31 2019-10-21 Bioverativ Therapeutics Inc Proteinas de fusion del factor ix y procedimientos de preparacion y utilizacion de las mismas.
MX2020012397A (es) 2018-05-18 2021-04-12 Bioverativ Therapeutics Inc Metodos de tratamiento de la hemofilia a.
MX2020013036A (es) 2018-06-05 2021-02-26 Amgen Inc Modulacion de la fagocitosis celular dependiente de anticuerpos.
CA3110530A1 (en) 2018-09-11 2020-03-19 Amgen Inc. Methods of modulating antibody-dependent cell-mediated cytotoxicity
WO2020086408A1 (en) 2018-10-26 2020-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A high-yield perfusion-based transient gene expression bioprocess
WO2020118069A2 (en) 2018-12-06 2020-06-11 Bioverativ Therapeutics Inc. Use of lentiviral vectors expressing factor ix
KR20220024628A (ko) 2019-06-19 2022-03-03 바이오버라티브 테라퓨틱스 인크. 혈우병 및 낮은 골 무기질 밀도를 치료하기 위한 재조합 인자 viii-fc
KR20220097891A (ko) 2019-09-30 2022-07-08 바이오버라티브 테라퓨틱스 인크. 렌티바이러스 벡터 제형
CN116033927A (zh) 2020-06-24 2023-04-28 比奥维拉迪维治疗股份有限公司 从经修饰以表达因子viii的慢病毒载体的制剂中去除游离因子viii的方法
AU2023261711A1 (en) * 2022-04-28 2024-11-21 Joint Stock Company "Biocad" Isolated nucleic acid that encodes fusion protein based on fviii-bdd and on heterologous signal peptide
CN114989307B (zh) * 2022-05-11 2023-08-01 华兰生物工程股份有限公司 一种重组人凝血因子Ⅷ-Fc融合蛋白及制备方法

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235881A (en) * 1978-12-04 1980-11-25 Cort Joseph H Method for producing high potency factor VIII
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
WO1986006101A1 (en) 1985-04-12 1986-10-23 Genetics Institute, Inc. Novel procoagulant proteins
KR910006424B1 (ko) 1985-08-21 1991-08-24 인코텍스 비.브이 편성브리프(brief) 제조방법
DE3785102T2 (de) 1986-01-03 1993-07-22 Genetics Inst Verfahren zur herstellung von faktor-viii:c-typ-proteinen.
US5595886A (en) 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US5610278A (en) 1986-06-24 1997-03-11 Novo Nordisk A/S Process for producing a coagulation active complex of factor VIII fragments
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
CA1331157C (en) 1987-04-06 1994-08-02 Randal J. Kaufman Method for producing factor viii:c-type proteins
US6060447A (en) 1987-05-19 2000-05-09 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
IL86693A (en) 1987-06-12 1994-06-24 Stichting Centraal Lab Proteins with factor VIII activity, process for their preparation using genetically engineered cells and pharmaceutical compositions containing them
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
DE3720246A1 (de) 1987-06-19 1988-12-29 Behringwerke Ag Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet
FR2619314B1 (fr) 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
US4994371A (en) 1987-08-28 1991-02-19 Davie Earl W DNA preparation of Christmas factor and use of DNA sequences
US5004803A (en) 1988-11-14 1991-04-02 Genetics Institute, Inc. Production of procoagulant proteins
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
CA2078721A1 (en) 1991-09-24 1993-03-25 Hiroshi Yonemura Process for preparing human coagulation factor viii protein complex
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6376463B1 (en) 1992-04-07 2002-04-23 Emory University Modified factor VIII
US5859204A (en) 1992-04-07 1999-01-12 Emory University Modified factor VIII
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US5563045A (en) 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
US6818439B1 (en) 1994-12-30 2004-11-16 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders
SE9503380D0 (sv) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
US6458563B1 (en) 1996-06-26 2002-10-01 Emory University Modified factor VIII
CA2225189C (en) 1997-03-06 2010-05-25 Queen's University At Kingston Canine factor viii gene, protein and methods of use
EP1252192B1 (en) 2000-02-11 2006-08-16 MERCK PATENT GmbH Enhancing the circulating half-life of antibody-based fusion proteins
JP2003530847A (ja) * 2000-04-12 2003-10-21 ヒューマン ゲノム サイエンシズ インコーポレイテッド アルブミン融合タンパク質
PL365293A1 (pl) * 2001-02-05 2004-12-27 Novo Nordisk Health Care Ag Skojarzone zastosowanie polipeptydów czynnika VIIi polipeptydów czynnika VIII
EP2277889B1 (en) 2001-12-21 2014-07-09 Human Genome Sciences, Inc. Fusion proteins of albumin and interferon beta
US7041635B2 (en) 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
EP1444986A1 (en) * 2003-02-07 2004-08-11 Aventis Behring GmbH Pharmaceutical preparation for the improved treatment of blood-clotting disorders
SI2298347T1 (sl) * 2003-05-06 2016-03-31 Biogen Hemophilia Inc. Himerni proteini s faktorjem strjevanja krvi za zdravljenje hemostatske motnje
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
TWI353991B (en) * 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
MXPA05013789A (es) * 2003-06-19 2006-06-27 Tanox Inc Composiciones y metodos para tratar los desordenes relacionados con la coagulacion.
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
ES2821832T3 (es) 2004-11-12 2021-04-27 Bayer Healthcare Llc Modificación de FVIII dirigida al sitio
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
EP1996937A4 (en) 2006-03-06 2009-04-08 Amunix Inc GENETIC PACKS AND USES THEREOF
KR20080108147A (ko) * 2006-03-31 2008-12-11 백스터 인터내셔널 인코포레이티드 페질화된 인자 ｖｉｉｉ
KR101542752B1 (ko) 2006-12-22 2015-08-10 체에스엘 베링 게엠베하 연장된 생체내 반감기를 갖는 변형된 응고 인자
BRPI0815416A2 (pt) 2007-08-15 2014-10-21 Amunix Inc Composições e métodos para modificar propriedades de polipeptídeos biologicamente ativos
KR101582841B1 (ko) * 2008-02-27 2016-01-11 노보 노르디스크 에이/에스 콘쥬게이트된 인자 ｖｉｉｉ 분자
US8800831B2 (en) 2009-08-19 2014-08-12 Larry A. Gray Multi-purpose rack and method thereof
KR101544245B1 (ko) 2009-02-03 2015-08-12 아뮤닉스 오퍼레이팅 인코포레이티드 연장된 재조합 폴리펩티드 및 이를 포함하는 조성물
CN102427823A (zh) * 2009-03-24 2012-04-25 拜耳医药保健有限公司 因子viii变体及使用方法
GB0908515D0 (en) 2009-05-18 2009-06-24 Apitope Technology Bristol Ltd Peptide
EP2506868B1 (en) 2009-12-06 2017-11-15 Bioverativ Therapeutics Inc. Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
HUE043763T2 (hu) 2011-07-08 2019-09-30 Bioverativ Therapeutics Inc VIII-as faktor kiméra és hibrid polipeptidek, és azok alkalmazási eljárásai
SI2802668T1 (sl) * 2012-01-12 2019-01-31 Bioverativ Therapeutics Inc. Zmanjšanje imunogeničnosti proti faktorju VIII pri posameznikih, ki se zdravijo zaradi faktorja VIII
ES2926798T3 (es) * 2013-03-15 2022-10-28 Bioverativ Therapeutics Inc Formulaciones de polipéptido de factor VIII
JP6083911B2 (ja) 2014-12-19 2017-02-22 花王株式会社 吸収性物品

Also Published As

Publication number Publication date
SG181130A1 (en) 2012-07-30
EP4382170A2 (en) 2024-06-12
AU2017268648B2 (en) 2019-01-31
CY1124888T1 (el) 2023-01-05
MX2012006347A (es) 2012-10-03
US9050318B2 (en) 2015-06-09
SG10201408049SA (en) 2015-02-27
EA038618B1 (ru) 2021-09-23
AU2016213822B2 (en) 2017-08-31
AU2017268648A1 (en) 2017-12-21
PT2506868T (pt) 2018-02-23
IL220204A0 (en) 2012-07-31
CA2782424C (en) 2021-07-27
SG10201907152YA (en) 2019-09-27
AU2021202912A1 (en) 2021-06-03
JP2022051964A (ja) 2022-04-01
JP6062459B2 (ja) 2017-01-18
ES2880038T3 (es) 2021-11-23
EP3906937A1 (en) 2021-11-10
ME02964B (me) 2018-07-20
MX382693B (es) 2025-03-13
KR101770849B1 (ko) 2017-09-05
MX353233B (es) 2018-01-08
PL2506868T3 (pl) 2018-06-29
EA025416B1 (ru) 2016-12-30
AU2010325787A2 (en) 2013-06-06
EP3326643A1 (en) 2018-05-30
AU2019202969A1 (en) 2019-05-16
HK1253887A1 (en) 2019-07-05
JP2015083608A (ja) 2015-04-30
EA201290443A1 (ru) 2013-06-28
IL260769B (en) 2020-03-31
HUE036233T2 (hu) 2018-06-28
BR112012013502A2 (pt) 2017-01-10
LT2506868T (lt) 2018-02-26
EP3326643B1 (en) 2021-04-07
HRP20211010T1 (hr) 2021-09-17
NZ600709A (en) 2015-01-30
EA201691109A1 (ru) 2017-01-30
AU2016213822A1 (en) 2016-09-01
HRP20180135T1 (hr) 2018-04-06
US11266720B2 (en) 2022-03-08
CA2782424A1 (en) 2011-06-09
MY159135A (en) 2016-12-15
JP6385410B2 (ja) 2018-09-05
JP2023071969A (ja) 2023-05-23
CA3121739A1 (en) 2011-06-09
IL220204B (en) 2018-08-30
JP6641340B2 (ja) 2020-02-05
ES2659888T3 (es) 2018-03-19
NO2506868T3 (pl) 2018-04-14
KR20120129882A (ko) 2012-11-28
EP2506868A2 (en) 2012-10-10
US20130108629A1 (en) 2013-05-02
CY1119919T1 (el) 2018-06-27
PT3326643T (pt) 2021-07-12
JP2018024706A (ja) 2018-02-15
AU2021202912B2 (en) 2024-08-01
EP4382170A3 (en) 2024-09-04
SI2506868T1 (en) 2018-04-30
US20190262429A1 (en) 2019-08-29
US9241978B2 (en) 2016-01-26
AU2010325787B2 (en) 2016-05-12
AU2024227757A1 (en) 2024-11-21
EP2506868B1 (en) 2017-11-15
RS56957B1 (sr) 2018-05-31
MX336830B (es) 2016-02-03
US20160199455A1 (en) 2016-07-14
CN102791285A (zh) 2012-11-21
SMT201800099T1 (it) 2018-03-08
EP2506868A4 (en) 2013-07-24
ZA201204874B (en) 2016-06-29
AU2010325787A1 (en) 2012-07-12
NZ703153A (en) 2015-02-27
JP2013512678A (ja) 2013-04-18
WO2011069164A2 (en) 2011-06-09
WO2011069164A3 (en) 2011-07-28
JP7244688B2 (ja) 2023-03-22
CO6561782A2 (es) 2012-11-15
JP2017025098A (ja) 2017-02-02
JP2025083451A (ja) 2025-05-30
JP2020019821A (ja) 2020-02-06
US20130274194A1 (en) 2013-10-17
AU2010325787A8 (en) 2012-07-19
JP5903048B2 (ja) 2016-04-13
US20220265780A1 (en) 2022-08-25
DK2506868T3 (da) 2018-01-29

Similar Documents

Publication Publication Date Title
IL260769B (en) Factor viii–fc chimeric and hybrid polypeptides and methods of using them
IL271870B (en) Factor viii chimeric and hybrid polypeptides and methods of using them
IL261147A (en) Methods for purification of polypeptides
SG184289A1 (en) Novel peptides and methods for their preparation and use
ZA201300994B (en) Polypeptides
IL222027A (en) Peptides and their use
GB0916576D0 (en) Polypeptides and uses thereof
GB0916578D0 (en) Polypeptides and uses thereof
EP2580231A4 (en) PEPTIDES, CONSTRUCTIONS AND USES THEREOF
ZA201200167B (en) Methods of generating hybrid/chimeric cells, and uses thereof
GB0905790D0 (en) Novel polypeptides and use thereof
ZA201007681B (en) Cd4-related polypeptides and methods of use
GB201010202D0 (en) Fusion polypeptides